Drugs / Plasma-derived antithrombin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01384903 Comparator | Jun 2011 → May 2013 | disseminated intravascular coagulation | Kyowa Kirin, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plasma-derived antithrombin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01384903 ↗ |
| Known as | pAT | “To compare the efficacy and safety of AT gamma to plasma-derived AT (pAT), we conducted a randomized, open-label, multicenter trial in patients with sepsis-induced disseminated...” PMID 30473794 ↗ Nov 2018 |
| Modality | Protein / enzyme biologic | “AT derived from human plasma” PMID 30473794 ↗ Nov 2018 |